Literature DB >> 19586418

Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection.

Quinton O King1, Benfang Lei, Allen G Harmsen.   

Abstract

We compared the growth of Streptococcus pneumoniae mutants with a disruption in the gene for either pneumococcal surface protein A (PspA-), neuraminidase A (NanA-), or hyaluronidase (Hyl-) to that of the parental strain D39 by means of a competitive growth model in mice with and those without prior influenza virus infection. The numbers of total bacteria recovered from mice with prior influenza virus infection were significantly greater than those recovered from mice without prior influenza virus infection. Although the Hyl- and NanA- mutants did not display attenuation in mice with or without prior influenza virus infection, the PspA- mutant exhibited attenuation both in mice with and in mice without prior influenza virus infection. This defect was severe in influenza virus-infected mice, for which growth of the PspA- mutant was 1800-fold lower than that of the parental strain D39. Furthermore, PspA immunization significantly reduced secondary bacterial lung burdens and concentrations of specific markers of lung damage in mice receiving serotypes 2, 3, and 4 pneumococci. Our findings indicate that PspA contributes to secondary S. pneumoniae infection after influenza virus infection and that PspA immunization mitigates early secondary pneumococcal lung infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19586418      PMCID: PMC2735857          DOI: 10.1086/600871

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.

Authors:  C Cornu; D Yzèbe; P Léophonte; J Gaillat; J P Boissel; M Cucherat
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

2.  RegR, a global LacI/GalR family regulator, modulates virulence and competence in Streptococcus pneumoniae.

Authors:  Sabine Chapuy-Regaud; A David Ogunniyi; Nicole Diallo; Yvette Huet; Jean-François Desnottes; James C Paton; Sonia Escaich; Marie-Claude Trombe
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

3.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

4.  Comparison of structural changes of cell surface carbohydrates in the eustachian tube epithelium of chinchillas infected with a Streptococcus pneumoniae neuraminidase-deficient mutant or its isogenic parent strain.

Authors:  H H Tong; M James; I Grants; X Liu; G Shi; T F DeMaria
Journal:  Microb Pathog       Date:  2001-12       Impact factor: 3.738

5.  Mechanism of hyaluronan degradation by Streptococcus pneumoniae hyaluronate lyase. Structures of complexes with the substrate.

Authors:  Mark J Jedrzejas; Luciane V Mello; Bert L de Groot; Songlin Li
Journal:  J Biol Chem       Date:  2002-05-03       Impact factor: 5.157

6.  Methodology for the measurement of mucociliary function in the mouse by scintigraphy.

Authors:  W M Foster; D M Walters; M Longphre; K Macri; L M Miller
Journal:  J Appl Physiol (1985)       Date:  2001-03

7.  Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.

Authors:  Jonathan A McCullers; Kimberly C Bartmess
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

8.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Authors:  D E Briles; S K Hollingshead; J King; A Swift; P A Braun; M K Park; L M Ferguson; M H Nahm; G S Nabors
Journal:  J Infect Dis       Date:  2000-11-08       Impact factor: 5.226

Review 9.  Pneumococcal virulence factors: structure and function.

Authors:  M J Jedrzejas
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

10.  Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae.

Authors:  A D Ogunniyi; R L Folland; D E Briles; S K Hollingshead; J C Paton
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

View more
  16 in total

1.  Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.

Authors:  Maria Hedlund; Laura M Aschenbrenner; Kellie Jensen; Jeffrey L Larson; Fang Fang
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

2.  Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.

Authors:  John T Wren; Lance K Blevins; Bing Pang; Ankita Basu Roy; Melissa B Oliver; Jennifer L Reimche; Jessie E Wozniak; Martha A Alexander-Miller; W Edward Swords
Journal:  Infect Immun       Date:  2017-03-23       Impact factor: 3.441

3.  Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza.

Authors:  Wilbur H Chen; Franklin R Toapanta; Kari Ann Shirey; Lei Zhang; Angeliki Giannelou; Carly Page; Matthew B Frieman; Stefanie N Vogel; Alan S Cross
Journal:  Immunol Lett       Date:  2011-10-20       Impact factor: 3.685

Review 4.  The role of influenza in the severity and transmission of respiratory bacterial disease.

Authors:  Michael J Mina; Keith P Klugman
Journal:  Lancet Respir Med       Date:  2014-08-15       Impact factor: 30.700

5.  The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.

Authors:  Calvin C Daniels; Patricia Coan; Janice King; Joanetha Hale; Kimberly A Benton; David E Briles; Susan K Hollingshead
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

Review 6.  Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications.

Authors:  Koenraad F van der Sluijs; Tom van der Poll; René Lutter; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

7.  Transcriptional adaptation of pneumococci and human pharyngeal cells in the presence of a virus infection.

Authors:  Sheila Z Kimaro Mlacha; Teresa C T Peret; Nikhil Kumar; Sandra Romero-Steiner; Julie C Dunning Hotopp; Nadeeza Ishmael; Valerie Grinblat-Huse; David R Riley; Dean D Erdman; George M Carlone; Jacquelyn Sampson; J Anthony G Scott; Hervé Tettelin
Journal:  BMC Genomics       Date:  2013-06-07       Impact factor: 3.969

8.  Evaluation of coseasonality of influenza and invasive pneumococcal disease: results from prospective surveillance.

Authors:  Stefan P Kuster; Ashleigh R Tuite; Jeffrey C Kwong; Allison McGeer; David N Fisman
Journal:  PLoS Med       Date:  2011-06-07       Impact factor: 11.069

9.  Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.

Authors:  Christopher J Greene; Laura R Marks; John C Hu; Ryan Reddinger; Lorrie Mandell; Hazeline Roche-Hakansson; Natalie D King-Lyons; Terry D Connell; Anders P Hakansson
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

10.  Streptococcus pneumoniae binds to host GAPDH on dying lung epithelial cells worsening secondary infection following influenza.

Authors:  Sang-Sang Park; Norberto Gonzalez-Juarbe; Ashleigh N Riegler; Hansol Im; Yvette Hale; Maryann P Platt; Christina Croney; David E Briles; Carlos J Orihuela
Journal:  Cell Rep       Date:  2021-06-15       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.